Chapter 9 of 25
- POLEmut: qualifying pathogenic proofreading mutation
- MMRd: defective DNA mismatch repair
- p53abn: abnormal p53 biology after classifier integration
- NSMP: none of the other groups; grade and ER refine risk
What you will learn
- Understand POLE-mutated, MMRd, p53-abnormal and NSMP cancers.
- Recognize how multiple findings are interpreted.
- Avoid assuming that one biomarker determines every treatment decision.
POLE-mutated disease
POLE helps copy DNA accurately. Certain pathogenic mutations in its proofreading region create a characteristic tumour group. In cancers confined to the uterus or cervix, this group generally has an excellent prognosis and can support reducing or omitting postoperative treatment in appropriate guideline-defined situations. It does not mean the person has inherited a POLE syndrome.
Not every POLE variant qualifies. A variant of uncertain significance or a nonqualifying change must not be used to label a cancer favourable. Evidence is less secure for advanced POLE-mutated disease; it should not automatically be managed as low risk or downstaged from stage III or IV.
Mismatch repair deficient disease
Mismatch repair proteins correct copying errors in DNA. When this system is deficient, abbreviated MMRd or dMMR, errors accumulate and the cancer may also be microsatellite instability-high, or MSI-H. This biological pattern is important for immunotherapy sensitivity and possible Lynch syndrome evaluation. Many MMRd cancers are caused by acquired changes rather than an inherited mutation.
MMRd does not guarantee an immunotherapy response, and it does not mean every early-stage patient needs immunotherapy. The disease setting, recurrence risk, prior therapy and local approval determine whether treatment is appropriate. A tumour's repair status and a person's inherited genetic status are distinct questions.
p53-abnormal disease
Abnormal p53 staining can indicate a tumour driven by changes in the TP53 pathway. This group often has a higher recurrence risk, particularly with invasion or extrauterine spread. It can strengthen the rationale for combined systemic and local treatment in appropriate high-risk settings. A p53-abnormal tumour result does not automatically imply an inherited TP53 syndrome.
The pathologist interprets the staining pattern, not simply whether some cells are “positive.” Diffuse overexpression, complete absence and other abnormal patterns require appropriate controls and expertise. Unexpected results may need review.
No specific molecular profile
NSMP means the tumour does not fit the other three categories after the required tests. It does not mean no molecular changes exist or that the cancer is harmless. The group is diverse. The 2025 ESGO–ESTRO–ESP guidance further separates low-grade, estrogen-receptor-positive NSMP disease from high-grade or ER-negative NSMP disease for risk assessment.
ER results, grade, LVSI and stage therefore remain important within NSMP. A broad statement that all NSMP cancers have an “intermediate prognosis” hides clinically meaningful differences.
How classification works
| Result pattern | General interpretation |
|---|---|
| Qualifying pathogenic POLE mutation | POLE group usually takes precedence in multiple-classifier tumours |
| MMR deficiency without qualifying POLE mutation | MMRd generally takes precedence over secondary abnormal p53 |
| Abnormal p53 without the above classifiers | p53-abnormal group |
| None of the above after adequate testing | NSMP; grade and ER further refine risk |
This is an educational summary, not a tool for self-classification. Some tumours have more than one abnormal test. Expert pathology review prevents a secondary p53 change from incorrectly overriding a POLE or MMRd classification. If POLE testing has not been done, the team should explain the limits of the provisional label and whether testing could change management.
Questions and take-home messages
Ask which tests established your group, whether a variant is pathogenic, and how the result changes your actual options. Molecular classification improves decisions but cannot predict an individual's future with certainty. RAINBO and other studies are testing more tailored treatment; research strategies should not be mistaken for completed evidence.
Related chapters
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- Berek et al. FIGO staging of endometrial cancer, 2023
- RAINBO molecularly directed research programme protocol, 2023
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy